Marzena Chrapczyńska
Marzena Chrapczyńska has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Agnieszka Filarecka
MD, Dr Tytus Chałubiński District Hospital in Zakopane, Zakopane, Poland
10 shared publications - Aleksandra Siegmund
Medical University of Silesia in Katowice, Katowice, Silesia, Poland
10 shared publications - Emilia Przybyszewska
AVO-DENTAL" Dentistry & Aesthetic Medicine in Zakopane, Poland
10 shared publications - Julia Gatniejewska
Independent Researcher, Poland
10 shared publications - Martyna Sienicka
Instytut „Centrum Zdrowia Matki Polki” w Łodzi, Poland
10 shared publications - Paulina Prudzic
Independent Researcher, Poland
10 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
LIFESTYLE INTERVENTIONS FOR CHILDHOOD OVERWEIGHT AND OBESITY: NARRATIVE REVIEW OF RANDOMIZED CONTROLLED TRIALS
Childhood overweight and obesity remain major global public health challenges associated with increased cardiometabolic risk, psychosocial complications, and persistence into adulthood. Lifestyle interventions are considered the first-line strategy for obesity prevention and treatment in pediatric populations. The aim of this systematic review was to evaluate the effectiveness of lifestyle interventions in preventing and treating overweight and obesity among children and adolescents aged 0–18 years. A systematic literature review of randomized controlled trials published between January 2016 and March 2026 was conducted using PubMed and Google Scholar databases. Studies involving dietary, physical activity, behavioral, family-based, school-based, or technology-assisted interventions were included. Following screening and eligibility assessment, 39 randomized controlled trials were included in the narrative synthesis. Most interventions combined nutritional education, physical activity, behavioral strategies, and family or school involvement. Family-based and intensive multicomponent interventions demonstrated the most consistent improvements in body mass index (BMI) and health-related behaviors. School-based interventions generally improved lifestyle behaviors; however, their effects on anthropometric outcomes were less consistent. Technology-assisted interventions, including exergaming and wearable devices, produced mixed results. Several studies also reported improvements in metabolic parameters, physical activity, and quality of life despite modest BMI reductions. Overall, lifestyle interventions may support the prevention and treatment of childhood obesity, although their effects on BMI are generally moderate. The most effective interventions appear to be intensive, family-centered, and multicomponent. Future research should focus on long-term follow-up, implementation feasibility, and sustainable intervention strategies.
- 18 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessLIFESTYLE INTERVENTIONS FOR CHILDHOOD OVERWEIGHT AND OBESITY: NARRATIVE REVIEW OF RANDOMIZED CONTROLLED TRIALS
Childhood overweight and obesity remain major global public health challenges associated with increased cardiometabolic risk, psychosocial complications, and persistence into adulthood. Lifestyle interventions are considered the first-line strategy for obesity prevention and treatment in pediatric populations. The aim of this systematic review was to evaluate the effectiveness of lifestyle interventions in preventing and treating overweight and obesity among children and adolescents aged 0–18 years. A systematic literature review of randomized controlled trials published between January 2016 and March 2026 was conducted using PubMed and Google Scholar databases. Studies involving dietary, physical activity, behavioral, family-based, school-based, or technology-assisted interventions were included. Following screening and eligibility assessment, 39 randomized controlled trials were included in the narrative synthesis. Most interventions combined nutritional education, physical activity, behavioral strategies, and family or school involvement. Family-based and intensive multicomponent interventions demonstrated the most consistent improvements in body mass index (BMI) and health-related behaviors. School-based interventions generally improved lifestyle behaviors; however, their effects on anthropometric outcomes were less consistent. Technology-assisted interventions, including exergaming and wearable devices, produced mixed results. Several studies also reported improvements in metabolic parameters, physical activity, and quality of life despite modest BMI reductions. Overall, lifestyle interventions may support the prevention and treatment of childhood obesity, although their effects on BMI are generally moderate. The most effective interventions appear to be intensive, family-centered, and multicomponent. Future research should focus on long-term follow-up, implementation feasibility, and sustainable intervention strategies.
- Open Access
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
BIOLOGICAL TREATMENT OF SEVERE ASTHMA: A COMPARATIVE ANALYSIS OF TEZEPELUMAB, MEPOLIZUMAB, BENRALIZUMAB, AND DUPILUMAB
Introduction: Bronchial asthma remains a significant clinical problem despite advances in pharmacological treatment. Approximately 5–10% of asthma patients suffer from a severe, uncontrolled form of the disease associated with frequent exacerbations, impaired lung function, reduced quality of life, and increased hospitalization rates. The introduction of biologic therapies targeting Th2-dependent inflammatory pathways has significantly improved treatment outcomes in this group of patients. Aim of the Study: The aim of this study was to analyze and compare the efficacy and safety of biologic therapies used in the treatment of severe asthma, with particular emphasis on tezepelumab, mepolizumab, benralizumab, and dupilumab, based on clinical trials and real-world studies. Materials and Methods: A literature review was conducted using the PubMed database. Original clinical trials, prospective studies, and real-world observational studies published between 2020 and 2026 were included in the analysis. The effects of biologic therapies on asthma exacerbation reduction, improvement in lung function, reduction in oral corticosteroid use, achievement of clinical remission, and long-term treatment safety were evaluated. Results: All analyzed biologic therapies demonstrated significant clinical efficacy in the treatment of severe asthma. Tezepelumab led to a substantial reduction in the number of exacerbations, improvement in pulmonary function parameters, and reduction in oral corticosteroid use regardless of eosinophil levels. Mepolizumab and benralizumab showed comparable efficacy, particularly in patients with eosinophilic asthma. Dupilumab demonstrated high efficacy in patients with type 2 inflammation, especially regarding improvement in lung function. Real-world studies confirmed the effectiveness and favorable safety profile of biologic therapies observed in randomized clinical trials. Conclusions: Biologic therapies constitute an effective and safe treatment option for severe asthma and significantly improve disease control and patients’ quality of life. The strongest clinical evidence concerns tezepelumab, mepolizumab, benralizumab, and dupilumab; however, treatment efficacy may depend on the disease phenotype and inflammatory biomarkers. Further studies are needed to optimize the personalization of biologic therapies and to standardize remission criteria in severe asthma.
- 31 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessBIOLOGICAL TREATMENT OF SEVERE ASTHMA: A COMPARATIVE ANALYSIS OF TEZEPELUMAB, MEPOLIZUMAB, BENRALIZUMAB, AND DUPILUMAB
Introduction: Bronchial asthma remains a significant clinical problem despite advances in pharmacological treatment. Approximately 5–10% of asthma patients suffer from a severe, uncontrolled form of the disease associated with frequent exacerbations, impaired lung function, reduced quality of life, and increased hospitalization rates. The introduction of biologic therapies targeting Th2-dependent inflammatory pathways has significantly improved treatment outcomes in this group of patients. Aim of the Study: The aim of this study was to analyze and compare the efficacy and safety of biologic therapies used in the treatment of severe asthma, with particular emphasis on tezepelumab, mepolizumab, benralizumab, and dupilumab, based on clinical trials and real-world studies. Materials and Methods: A literature review was conducted using the PubMed database. Original clinical trials, prospective studies, and real-world observational studies published between 2020 and 2026 were included in the analysis. The effects of biologic therapies on asthma exacerbation reduction, improvement in lung function, reduction in oral corticosteroid use, achievement of clinical remission, and long-term treatment safety were evaluated. Results: All analyzed biologic therapies demonstrated significant clinical efficacy in the treatment of severe asthma. Tezepelumab led to a substantial reduction in the number of exacerbations, improvement in pulmonary function parameters, and reduction in oral corticosteroid use regardless of eosinophil levels. Mepolizumab and benralizumab showed comparable efficacy, particularly in patients with eosinophilic asthma. Dupilumab demonstrated high efficacy in patients with type 2 inflammation, especially regarding improvement in lung function. Real-world studies confirmed the effectiveness and favorable safety profile of biologic therapies observed in randomized clinical trials. Conclusions: Biologic therapies constitute an effective and safe treatment option for severe asthma and significantly improve disease control and patients’ quality of life. The strongest clinical evidence concerns tezepelumab, mepolizumab, benralizumab, and dupilumab; however, treatment efficacy may depend on the disease phenotype and inflammatory biomarkers. Further studies are needed to optimize the personalization of biologic therapies and to standardize remission criteria in severe asthma.
- Open Access
- 25 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
POLYPHARMACY IN AGEING POPULATIONS: NEUROLOGICAL RISKS, HEALTHCARE DETERMINANTS AND DIGITAL INTERVENTIONS IN EUROPE
As Europe’s population ages, managing polypharmacy has evolved from an individual clinical concern into a major public health priority [3, 4]. Broadly driven by multi-organ chronic diseases and uncoordinated specialist care, the accumulation of multiple drug prescriptions generates heavy clinical and economic costs [5, 6]. This narrative review maps the neurological risks linked to polypharmacy and evaluates the structural healthcare factors that shape prescribing habits across European nations [1, 12]. Gathering data published between 2010 and 2024, we synthesized evidence regarding regional prevalence, cumulative anticholinergic burden, and system-level weaknesses [4, 14]. Current statistics reveal that 40–50% of older Europeans aged ≥ 65 years face polypharmacy, though rates differ widely between countries [4, 24]. The central nervous system bears a disproportionate share of drug-induced harm; common outcomes include accelerated cognitive decline, acute delirium, motor instabilities, and the worsening of pre-existing psychiatric or epileptic conditions [13, 14, 19]. Much of this damage stems directly from an unmonitored anticholinergic burden, which tracks closely with elevated dementia rates and mortality [15, 16]. At the institutional level, fragmented communication between physicians, poor access to comprehensive geriatric assessments, and the absence of routine medication reviews act as primary drivers of unsafe prescribing [2, 26]. Mitigating these risks requires integrating targeted organizational shifts—such as mandatory deprescribing protocols and clinical pharmacist oversight—with digital infrastructure, including artificial intelligence platforms and clinical decision-support software [7, 31, 33, 34].
- 25 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessPOLYPHARMACY IN AGEING POPULATIONS: NEUROLOGICAL RISKS, HEALTHCARE DETERMINANTS AND DIGITAL INTERVENTIONS IN EUROPE
As Europe’s population ages, managing polypharmacy has evolved from an individual clinical concern into a major public health priority [3, 4]. Broadly driven by multi-organ chronic diseases and uncoordinated specialist care, the accumulation of multiple drug prescriptions generates heavy clinical and economic costs [5, 6]. This narrative review maps the neurological risks linked to polypharmacy and evaluates the structural healthcare factors that shape prescribing habits across European nations [1, 12]. Gathering data published between 2010 and 2024, we synthesized evidence regarding regional prevalence, cumulative anticholinergic burden, and system-level weaknesses [4, 14]. Current statistics reveal that 40–50% of older Europeans aged ≥ 65 years face polypharmacy, though rates differ widely between countries [4, 24]. The central nervous system bears a disproportionate share of drug-induced harm; common outcomes include accelerated cognitive decline, acute delirium, motor instabilities, and the worsening of pre-existing psychiatric or epileptic conditions [13, 14, 19]. Much of this damage stems directly from an unmonitored anticholinergic burden, which tracks closely with elevated dementia rates and mortality [15, 16]. At the institutional level, fragmented communication between physicians, poor access to comprehensive geriatric assessments, and the absence of routine medication reviews act as primary drivers of unsafe prescribing [2, 26]. Mitigating these risks requires integrating targeted organizational shifts—such as mandatory deprescribing protocols and clinical pharmacist oversight—with digital infrastructure, including artificial intelligence platforms and clinical decision-support software [7, 31, 33, 34].
- Open Access
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
OPTIMIZATION OF REHABILITATION PROTOCOLS AFTER ELECTIVE HIP REPLACEMENT IN LIGHT OF CURRENT SCIENTIFIC EVIDENCE
Introduction: Hip replacement is one of the most effective treatments for advanced degenerative disease, but the optimal postoperative rehabilitation model remains a matter of debate. Objective: The aim of this study was to evaluate current rehabilitation protocols used after elective hip replacement and identify their most important and best-documented elements. Methods: A narrative literature review was conducted, encompassing 34 publications from 2015–2025, including randomized controlled trials, systematic reviews, meta-analyses, clinical guidelines, and epidemiological data. PubMed and Google Scholar databases were searched using predefined inclusion and exclusion criteria. The timing of rehabilitation initiation, type of intervention, therapy organization, and their impact on pain and functional outcomes were analyzed. Main Findings: Available evidence confirms that rehabilitation after elective hip replacement promotes improved function, independence, and pain reduction. Promising results have been reported for early mobilization, resistance exercises, functional training, and multicomponent approaches, including patient education and gait retraining. Early mobilization, often on the day of surgery, can shorten hospitalization, while training programs improve functional outcomes, as assessed by the Harris Hip Score, among other measures. However, no clear advantage of one universal rehabilitation model over others has been demonstrated. Conclusions: Rehabilitation is a key element of treatment after elective hip replacement, significantly improving function and reducing pain. Current evidence supports early, individually tailored, and comprehensive therapy, including mobilization and targeted strength training. Further high-quality methodological research aimed at standardizing treatment is necessary.
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessOPTIMIZATION OF REHABILITATION PROTOCOLS AFTER ELECTIVE HIP REPLACEMENT IN LIGHT OF CURRENT SCIENTIFIC EVIDENCE
Introduction: Hip replacement is one of the most effective treatments for advanced degenerative disease, but the optimal postoperative rehabilitation model remains a matter of debate. Objective: The aim of this study was to evaluate current rehabilitation protocols used after elective hip replacement and identify their most important and best-documented elements. Methods: A narrative literature review was conducted, encompassing 34 publications from 2015–2025, including randomized controlled trials, systematic reviews, meta-analyses, clinical guidelines, and epidemiological data. PubMed and Google Scholar databases were searched using predefined inclusion and exclusion criteria. The timing of rehabilitation initiation, type of intervention, therapy organization, and their impact on pain and functional outcomes were analyzed. Main Findings: Available evidence confirms that rehabilitation after elective hip replacement promotes improved function, independence, and pain reduction. Promising results have been reported for early mobilization, resistance exercises, functional training, and multicomponent approaches, including patient education and gait retraining. Early mobilization, often on the day of surgery, can shorten hospitalization, while training programs improve functional outcomes, as assessed by the Harris Hip Score, among other measures. However, no clear advantage of one universal rehabilitation model over others has been demonstrated. Conclusions: Rehabilitation is a key element of treatment after elective hip replacement, significantly improving function and reducing pain. Current evidence supports early, individually tailored, and comprehensive therapy, including mobilization and targeted strength training. Further high-quality methodological research aimed at standardizing treatment is necessary.
- Open Access
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
EFFECTS OF BIOLOGIC THERAPIES ON SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NARRATIVE REVIEW
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease causing progressive joint destruction, pain, disability, and reduced quality of life. Many patients respond inadequately to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), necessitating more effective treatment strategies. Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic therapies have transformed RA management by targeting inflammatory pathways such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and Janus kinase (JAK) signaling. Methods: A narrative-systematic review of randomized clinical trials and observational studies was conducted to evaluate the efficacy and safety of biologic therapies in RA patients with inadequate response to csDMARDs. Outcomes included ACR20/50/70 response rates, Disease Activity Score in 28 joints (DAS28), remission rates, functional outcomes, and adverse events. Results: Biologic therapies significantly reduced disease activity and improved patient outcomes. TNF inhibitors combined with methotrexate achieved the most consistent efficacy, with ACR20, ACR50, and ACR70 responses reaching 78%, 57%, and 31%, respectively. Remission rates approached 40–50% in several studies. IL-6 inhibitors and JAK inhibitors provided rapid pain relief and functional improvement. Overall, remission or low disease activity was achieved in 30–60% of patients. Although biologic therapies increased the risk of adverse events, particularly infections, their safety profile remained acceptable with proper monitoring. Discussion: The findings demonstrate that biologic and targeted therapies represent a major advancement in RA treatment, particularly in patients resistant to conventional therapies. Differences in efficacy and safety profiles support individualized treatment selection, while methotrexate combination therapy may further enhance clinical response. Conclusion: Biologic therapies substantially improve disease control, physical function, and quality of life in RA patients. TNF inhibitors, IL-6 inhibitors, and JAK inhibitors remain central to modern RA management, although continued long-term safety monitoring and personalized therapeutic strategies are essential.
- 24 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessEFFECTS OF BIOLOGIC THERAPIES ON SYMPTOMS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NARRATIVE REVIEW
Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory disease causing progressive joint destruction, pain, disability, and reduced quality of life. Many patients respond inadequately to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), necessitating more effective treatment strategies. Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) and targeted synthetic therapies have transformed RA management by targeting inflammatory pathways such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and Janus kinase (JAK) signaling. Methods: A narrative-systematic review of randomized clinical trials and observational studies was conducted to evaluate the efficacy and safety of biologic therapies in RA patients with inadequate response to csDMARDs. Outcomes included ACR20/50/70 response rates, Disease Activity Score in 28 joints (DAS28), remission rates, functional outcomes, and adverse events. Results: Biologic therapies significantly reduced disease activity and improved patient outcomes. TNF inhibitors combined with methotrexate achieved the most consistent efficacy, with ACR20, ACR50, and ACR70 responses reaching 78%, 57%, and 31%, respectively. Remission rates approached 40–50% in several studies. IL-6 inhibitors and JAK inhibitors provided rapid pain relief and functional improvement. Overall, remission or low disease activity was achieved in 30–60% of patients. Although biologic therapies increased the risk of adverse events, particularly infections, their safety profile remained acceptable with proper monitoring. Discussion: The findings demonstrate that biologic and targeted therapies represent a major advancement in RA treatment, particularly in patients resistant to conventional therapies. Differences in efficacy and safety profiles support individualized treatment selection, while methotrexate combination therapy may further enhance clinical response. Conclusion: Biologic therapies substantially improve disease control, physical function, and quality of life in RA patients. TNF inhibitors, IL-6 inhibitors, and JAK inhibitors remain central to modern RA management, although continued long-term safety monitoring and personalized therapeutic strategies are essential.
- Open Access
- 21 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
DIFFERENTIAL EFFECTS OF SPECIFIC SOCIAL MEDIA PLATFORMS (TIKTOK, INSTAGRAM, YOUTUBE) ON MENTAL HEALTH OUTCOMES IN ADOLESCENTS: A SYSTEMATIC REVIEW
Background. Social media use among children and adolescents has expanded rapidly over the past decade, but most empirical work has examined screen time as a single construct, ignoring meaningful differences between platforms. Objective. This systematic review examined whether use of TikTok, Instagram, and YouTube is associated with distinct mental health outcomes in young people aged 6–18 years. Methods. PubMed and Google Scholar were searched between January and March 2026 in line with the PRISMA 2020 guidelines. Eligible records reported quantitative or qualitative data on at least one of the three platforms in relation to depression, anxiety, body image, self-esteem, problematic or addictive use, or general wellbeing. Methodological quality was rated with the Newcastle–Ottawa Scale for observational studies and AMSTAR-2 for evidence syntheses. Of 257 identified records, 32 met the inclusion criteria. Results. TikTok use was the most consistently linked to harm: depressive and anxiety symptoms, problematic use, and body-image disturbance, with a particularly strong contribution from algorithmic content delivery. Instagram findings centred on appearance comparison, body dissatisfaction, and self-criticism, and these effects tracked content type more closely than time on the platform. YouTube produced a more heterogeneous picture, including improvements in mental health literacy alongside concerns about uneven information quality and exposure to body-related content such as mukbang videos. Conclusion. Total time on social media is a poor proxy for risk. Platform design, content type, and algorithmic curation appear to drive distinct outcomes, and policy and clinical responses should be tailored accordingly.
- 21 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessDIFFERENTIAL EFFECTS OF SPECIFIC SOCIAL MEDIA PLATFORMS (TIKTOK, INSTAGRAM, YOUTUBE) ON MENTAL HEALTH OUTCOMES IN ADOLESCENTS: A SYSTEMATIC REVIEW
Background. Social media use among children and adolescents has expanded rapidly over the past decade, but most empirical work has examined screen time as a single construct, ignoring meaningful differences between platforms. Objective. This systematic review examined whether use of TikTok, Instagram, and YouTube is associated with distinct mental health outcomes in young people aged 6–18 years. Methods. PubMed and Google Scholar were searched between January and March 2026 in line with the PRISMA 2020 guidelines. Eligible records reported quantitative or qualitative data on at least one of the three platforms in relation to depression, anxiety, body image, self-esteem, problematic or addictive use, or general wellbeing. Methodological quality was rated with the Newcastle–Ottawa Scale for observational studies and AMSTAR-2 for evidence syntheses. Of 257 identified records, 32 met the inclusion criteria. Results. TikTok use was the most consistently linked to harm: depressive and anxiety symptoms, problematic use, and body-image disturbance, with a particularly strong contribution from algorithmic content delivery. Instagram findings centred on appearance comparison, body dissatisfaction, and self-criticism, and these effects tracked content type more closely than time on the platform. YouTube produced a more heterogeneous picture, including improvements in mental health literacy alongside concerns about uneven information quality and exposure to body-related content such as mukbang videos. Conclusion. Total time on social media is a poor proxy for risk. Platform design, content type, and algorithmic curation appear to drive distinct outcomes, and policy and clinical responses should be tailored accordingly.
- Open Access
- 20 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
THE LOW-FODMAP DIET IN IRRITABLE BOWEL SYNDROME: EFFECTIVENESS, LIMITATIONS, AND PRACTICAL IMPLICATIONS - A NARRATIVE REVIEW
Introduction: Irritable bowel syndrome is characterized by symptoms such as abdominal pain associated with defecation and changes in stool frequency and/or consistency. In recent years, the low-FODMAP diet has become one of the most commonly used dietary interventions. Aim of the study: The aim of this study was to assess the effectiveness of the low-FODMAP diet and to identify its limitations and consistency with current guidelines. Methods: A narrative review of the literature was conducted, including 31 publications from 2012–2026, such as original research articles, randomized controlled trials, systematic reviews, meta-analyses, and current clinical guidelines on the diagnosis and treatment of IBS. PubMed and Google Scholar databases were searched using predefined inclusion and exclusion criteria. Main findings: The results of the analyzed studies indicate that the low-FODMAP diet may reduce IBS symptoms such as bloating, abdominal pain, and intestinal discomfort. However, no clear superiority over other dietary strategies has been demonstrated. Clinical response varies and may depend on the patient’s gut microbiota. Data on the use of the low-FODMAP diet in the pediatric population and other special clinical groups are limited and do not allow definitive conclusions to be drawn. Conclusions: The low-FODMAP diet is an effective therapeutic option in selected patients with IBS; however, it should be implemented in stages, including elimination, reintroduction, and personalization phases. Supervision by a dietitian and individual adjustment of recommendations to the patient’s needs are recommended. Further studies are needed to assess the long-term effects of the diet and predictors of clinical response.
- 20 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessTHE LOW-FODMAP DIET IN IRRITABLE BOWEL SYNDROME: EFFECTIVENESS, LIMITATIONS, AND PRACTICAL IMPLICATIONS - A NARRATIVE REVIEW
Introduction: Irritable bowel syndrome is characterized by symptoms such as abdominal pain associated with defecation and changes in stool frequency and/or consistency. In recent years, the low-FODMAP diet has become one of the most commonly used dietary interventions. Aim of the study: The aim of this study was to assess the effectiveness of the low-FODMAP diet and to identify its limitations and consistency with current guidelines. Methods: A narrative review of the literature was conducted, including 31 publications from 2012–2026, such as original research articles, randomized controlled trials, systematic reviews, meta-analyses, and current clinical guidelines on the diagnosis and treatment of IBS. PubMed and Google Scholar databases were searched using predefined inclusion and exclusion criteria. Main findings: The results of the analyzed studies indicate that the low-FODMAP diet may reduce IBS symptoms such as bloating, abdominal pain, and intestinal discomfort. However, no clear superiority over other dietary strategies has been demonstrated. Clinical response varies and may depend on the patient’s gut microbiota. Data on the use of the low-FODMAP diet in the pediatric population and other special clinical groups are limited and do not allow definitive conclusions to be drawn. Conclusions: The low-FODMAP diet is an effective therapeutic option in selected patients with IBS; however, it should be implemented in stages, including elimination, reintroduction, and personalization phases. Supervision by a dietitian and individual adjustment of recommendations to the patient’s needs are recommended. Further studies are needed to assess the long-term effects of the diet and predictors of clinical response.
- Open Access
- 18 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
THE IMPACT OF PHYSICAL EXERCISE ON BLOOD PRESSURE REDUCTION: A NARRATIVE REVIEW
Background: Physical exercise is an important non-pharmacological strategy for reducing blood pressure (BP) and preventing cardiovascular disease. Methods: This narrative review analyzed evidence from randomized controlled trials, systematic reviews, and meta-analyses on the effects of different exercise modalities on BP reduction. Results: Aerobic, resistance, isometric, combined training, and high-intensity interval training (HIIT) all demonstrated significant antihypertensive effects. Aerobic exercise improved vascular function, resistance training enhanced functional capacity, and isometric exercise showed particularly strong reductions in systolic BP. Greater BP reductions were observed in hypertensive and resistant hypertensive populations. Conclusion: Regular physical exercise effectively reduces BP and should be considered a key component of hypertension prevention and management. Individualized and sustained exercise interventions may provide substantial cardiovascular benefits.
- 18 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessTHE IMPACT OF PHYSICAL EXERCISE ON BLOOD PRESSURE REDUCTION: A NARRATIVE REVIEW
Background: Physical exercise is an important non-pharmacological strategy for reducing blood pressure (BP) and preventing cardiovascular disease. Methods: This narrative review analyzed evidence from randomized controlled trials, systematic reviews, and meta-analyses on the effects of different exercise modalities on BP reduction. Results: Aerobic, resistance, isometric, combined training, and high-intensity interval training (HIIT) all demonstrated significant antihypertensive effects. Aerobic exercise improved vascular function, resistance training enhanced functional capacity, and isometric exercise showed particularly strong reductions in systolic BP. Greater BP reductions were observed in hypertensive and resistant hypertensive populations. Conclusion: Regular physical exercise effectively reduces BP and should be considered a key component of hypertension prevention and management. Individualized and sustained exercise interventions may provide substantial cardiovascular benefits.
- Open Access
- 17 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
EFFICACY OF ANTIDEPRESSANTS IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW
Background: Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which antidepressants are used to modulate pathways involved in symptom generation. Evidence for their efficacy remains heterogeneous across drug classes and outcomes. Aim: To systematically evaluate the efficacy of antidepressants in the treatment of IBS across pharmacological classes and outcome domains. Methods: The methodology and reporting structure of this review were informed by the PRISMA framework. Literature searches were conducted in PubMed and Google Scholar to identify studies evaluating antidepressants in adults with irritable bowel syndrome diagnosed according to Rome criteria. Randomized controlled trials were considered the primary source of evidence and were supplemented, where relevant, by open-label, mechanistic, and exploratory studies. Eligible studies reported validated clinical outcomes, including IBS symptom severity, abdominal pain, global improvement, and health-related quality of life. Owing to differences in study design, interventions, and outcome measures, findings were synthesized qualitatively. Results: Tricyclic antidepressants (TCAs) demonstrated the most consistent signal of benefit, particularly for IBS symptom severity, global improvement, and abdominal pain. Selective serotonin reuptake inhibitors (SSRIs) showed inconsistent findings across trials, with effects varying by outcome measure and study design. Evidence for serotonin–norepinephrine reuptake inhibitors (SNRIs) was limited, often derived from add-on or open-label studies, although some randomized trials reported improvements in symptom severity and quality of life. Data for other antidepressants were restricted to a small number of RCTs with endpoint-specific effects. Variability in outcome measures, including IBS-SSS, adequate relief, and quality-of-life instruments, contributed to heterogeneity in reported treatment effects. Conclusions: Antidepressants appear to have a role in IBS management, with the most consistent evidence observed for TCAs. Findings for SSRIs are inconclusive, while evidence for SNRIs and other agents remains limited. Interpretation is constrained by variability in outcome measures and study design. Further well-designed RCTs using standardized endpoints are required to better define the role of antidepressants in IBS.
- 17 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessEFFICACY OF ANTIDEPRESSANTS IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME: A SYSTEMATIC REVIEW
Background: Irritable bowel syndrome (IBS) is a disorder of gut–brain interaction in which antidepressants are used to modulate pathways involved in symptom generation. Evidence for their efficacy remains heterogeneous across drug classes and outcomes. Aim: To systematically evaluate the efficacy of antidepressants in the treatment of IBS across pharmacological classes and outcome domains. Methods: The methodology and reporting structure of this review were informed by the PRISMA framework. Literature searches were conducted in PubMed and Google Scholar to identify studies evaluating antidepressants in adults with irritable bowel syndrome diagnosed according to Rome criteria. Randomized controlled trials were considered the primary source of evidence and were supplemented, where relevant, by open-label, mechanistic, and exploratory studies. Eligible studies reported validated clinical outcomes, including IBS symptom severity, abdominal pain, global improvement, and health-related quality of life. Owing to differences in study design, interventions, and outcome measures, findings were synthesized qualitatively. Results: Tricyclic antidepressants (TCAs) demonstrated the most consistent signal of benefit, particularly for IBS symptom severity, global improvement, and abdominal pain. Selective serotonin reuptake inhibitors (SSRIs) showed inconsistent findings across trials, with effects varying by outcome measure and study design. Evidence for serotonin–norepinephrine reuptake inhibitors (SNRIs) was limited, often derived from add-on or open-label studies, although some randomized trials reported improvements in symptom severity and quality of life. Data for other antidepressants were restricted to a small number of RCTs with endpoint-specific effects. Variability in outcome measures, including IBS-SSS, adequate relief, and quality-of-life instruments, contributed to heterogeneity in reported treatment effects. Conclusions: Antidepressants appear to have a role in IBS management, with the most consistent evidence observed for TCAs. Findings for SSRIs are inconclusive, while evidence for SNRIs and other agents remains limited. Interpretation is constrained by variability in outcome measures and study design. Further well-designed RCTs using standardized endpoints are required to better define the role of antidepressants in IBS.
- Open Access
- 16 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
INSULIN RESISTANCE IN POLYCYSTIC OVARY SYNDROME: CLINICAL IMPLICATIONS AND IMPACT ON QUALITY OF LIFE — A NARRATIVE REVIEW
Polycystic ovary syndrome (PCOS) is a multifaceted endocrine and metabolic condition affecting women of reproductive age. While historically conceptualized as a reproductive disorder, current evidence indicates that PCOS extends beyond ovulatory dysfunction and hyperandrogenism to include significant metabolic, psychological, and quality of life consequences. Insulin resistance represents a core pathophysiological feature of the syndrome, contributing to hyperinsulinemia, exacerbation of androgen excess, menstrual irregularities, and long term metabolic risk. This narrative review synthesizes current literature on the mechanisms and clinical implications of insulin resistance in PCOS, drawing from peer reviewed studies, systematic reviews, meta analyses, and international guidelines. Evidence shows that insulin resistance is prevalent across PCOS phenotypes, including in women without obesity, and is strongly associated with impaired glucose metabolism, dyslipidemia, metabolic syndrome, and increased cardiometabolic vulnerability. Psychological burden is also substantial, with many women reporting depressive and anxiety symptoms, body image concerns, fertility related distress, and reduced overall wellbeing. Interactions between metabolic dysfunction, emotional health, and lifestyle factors further contribute to diminished health related quality of life. Collectively, these findings highlight the need for early metabolic assessment, individualized therapeutic strategies, and interdisciplinary care models addressing both physiological and psychosocial dimensions of PCOS. A comprehensive approach to insulin resistance may improve reproductive, metabolic, and psychological outcomes and support more patient centered long term management.
- 16 August 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 2 (3(51))
Open AccessINSULIN RESISTANCE IN POLYCYSTIC OVARY SYNDROME: CLINICAL IMPLICATIONS AND IMPACT ON QUALITY OF LIFE — A NARRATIVE REVIEW
Polycystic ovary syndrome (PCOS) is a multifaceted endocrine and metabolic condition affecting women of reproductive age. While historically conceptualized as a reproductive disorder, current evidence indicates that PCOS extends beyond ovulatory dysfunction and hyperandrogenism to include significant metabolic, psychological, and quality of life consequences. Insulin resistance represents a core pathophysiological feature of the syndrome, contributing to hyperinsulinemia, exacerbation of androgen excess, menstrual irregularities, and long term metabolic risk. This narrative review synthesizes current literature on the mechanisms and clinical implications of insulin resistance in PCOS, drawing from peer reviewed studies, systematic reviews, meta analyses, and international guidelines. Evidence shows that insulin resistance is prevalent across PCOS phenotypes, including in women without obesity, and is strongly associated with impaired glucose metabolism, dyslipidemia, metabolic syndrome, and increased cardiometabolic vulnerability. Psychological burden is also substantial, with many women reporting depressive and anxiety symptoms, body image concerns, fertility related distress, and reduced overall wellbeing. Interactions between metabolic dysfunction, emotional health, and lifestyle factors further contribute to diminished health related quality of life. Collectively, these findings highlight the need for early metabolic assessment, individualized therapeutic strategies, and interdisciplinary care models addressing both physiological and psychosocial dimensions of PCOS. A comprehensive approach to insulin resistance may improve reproductive, metabolic, and psychological outcomes and support more patient centered long term management.